Ghent University Academic Bibliography

Advanced

Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis : results from a randomised phase III trial (FUTURE 1)

Vibeke Strand, Philip Mease, Laure Gossec, Ori Elkayam, Filip Van den Bosch UGent, James Zuazo, Luminita Pricop and Shephard Mpofu (2017) ANNALS OF THE RHEUMATIC DISEASES. 76(1). p.203-207
abstract
Objective: To evaluate the effect of secukinumab on patient-reported outcomes (PROs) in subjects with active psoriatic arthritis (PsA) in the FUTURE 1 study. Methods: Subjects were randomised 1:1:1 to receive intravenous (i.v.) secukinumab 10 mg/kg at weeks 0, 2 and 4 followed by subcutaneous secukinumab 150 or 75 mg every 4 weeks or matching placebo until week 24. Results: At week 24, subjects receiving secukinumab i.v. -> 1 50 mg or i.v. -> 75 mg reported greater least squares mean changes from baseline than those receiving placebo in patient global assessment of disease activity (-20.6 and -20.0 vs -7.4, respectively), patient assessment of pain (-20.8 and -20.4 vs -6.7), psoriatic arthritis quality of life (-3.5 and -3.2 vs -0.4), Dermatology Life Quality Index (-8.8 and -7.9 vs 0.7); p<0.0001 vs placebo for both secukinumab groups for above PROs and Functional Assessment of Chronic Illness Therapy-Fatigue (6.74 (p<0.05 vs placebo) and 6.03 vs 4.00); all of which well exceeded minimum clinically important differences. Conclusions: In subjects with PsA, secukinumab treatment resulted in clinically meaningful improvements in global disease activity, pain, generic and disease-specific measures of health-related quality of life and fatigue.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
QUALITY-OF-LIFE, RHEUMATOID-ARTHRITIS, ANKYLOSING-SPONDYLITIS, PERSPECTIVE, CRITERIA, FATIGUE
journal title
ANNALS OF THE RHEUMATIC DISEASES
Ann. Rheum. Dis.
volume
76
issue
1
pages
203 - 207
Web of Science type
Article
Web of Science id
000392425200029
ISSN
0003-4967
DOI
10.1136/annrheumdis-2015-209055
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
8502214
handle
http://hdl.handle.net/1854/LU-8502214
date created
2017-01-16 10:41:50
date last changed
2017-06-22 13:58:27
@article{8502214,
  abstract     = {Objective: To evaluate the effect of secukinumab on patient-reported outcomes (PROs) in subjects with active psoriatic arthritis (PsA) in the FUTURE 1 study. 
Methods: Subjects were randomised 1:1:1 to receive intravenous (i.v.) secukinumab 10 mg/kg at weeks 0, 2 and 4 followed by subcutaneous secukinumab 150 or 75 mg every 4 weeks or matching placebo until week 24. 
Results: At week 24, subjects receiving secukinumab i.v. -{\textrangle} 1 50 mg or i.v. -{\textrangle} 75 mg reported greater least squares mean changes from baseline than those receiving placebo in patient global assessment of disease activity (-20.6 and -20.0 vs -7.4, respectively), patient assessment of pain (-20.8 and -20.4 vs -6.7), psoriatic arthritis quality of life (-3.5 and -3.2 vs -0.4), Dermatology Life Quality Index (-8.8 and -7.9 vs 0.7); p{\textlangle}0.0001 vs placebo for both secukinumab groups for above PROs and Functional Assessment of Chronic Illness Therapy-Fatigue (6.74 (p{\textlangle}0.05 vs placebo) and 6.03 vs 4.00); all of which well exceeded minimum clinically important differences. 
Conclusions: In subjects with PsA, secukinumab treatment resulted in clinically meaningful improvements in global disease activity, pain, generic and disease-specific measures of health-related quality of life and fatigue.},
  author       = {Strand, Vibeke and Mease, Philip and Gossec, Laure and Elkayam, Ori and Van den Bosch, Filip and Zuazo, James and Pricop, Luminita and Mpofu, Shephard},
  issn         = {0003-4967},
  journal      = {ANNALS OF THE RHEUMATIC DISEASES},
  keyword      = {QUALITY-OF-LIFE,RHEUMATOID-ARTHRITIS,ANKYLOSING-SPONDYLITIS,PERSPECTIVE,CRITERIA,FATIGUE},
  language     = {eng},
  number       = {1},
  pages        = {203--207},
  title        = {Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis : results from a randomised phase III trial (FUTURE 1)},
  url          = {http://dx.doi.org/10.1136/annrheumdis-2015-209055},
  volume       = {76},
  year         = {2017},
}

Chicago
Strand, Vibeke, Philip Mease, Laure Gossec, Ori Elkayam, Filip Van den Bosch, James Zuazo, Luminita Pricop, and Shephard Mpofu. 2017. “Secukinumab Improves Patient-reported Outcomes in Subjects with Active Psoriatic Arthritis : Results from a Randomised Phase III Trial (FUTURE 1).” Annals of the Rheumatic Diseases 76 (1): 203–207.
APA
Strand, V., Mease, P., Gossec, L., Elkayam, O., Van den Bosch, F., Zuazo, J., Pricop, L., et al. (2017). Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis : results from a randomised phase III trial (FUTURE 1). ANNALS OF THE RHEUMATIC DISEASES, 76(1), 203–207.
Vancouver
1.
Strand V, Mease P, Gossec L, Elkayam O, Van den Bosch F, Zuazo J, et al. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis : results from a randomised phase III trial (FUTURE 1). ANNALS OF THE RHEUMATIC DISEASES. 2017;76(1):203–7.
MLA
Strand, Vibeke, Philip Mease, Laure Gossec, et al. “Secukinumab Improves Patient-reported Outcomes in Subjects with Active Psoriatic Arthritis : Results from a Randomised Phase III Trial (FUTURE 1).” ANNALS OF THE RHEUMATIC DISEASES 76.1 (2017): 203–207. Print.